Prosecution Insights
Last updated: November 15, 2026
Application No. 17/825,346

Method for Removing and/or Detecting Nucleic Acids Having Mismatched Nucleotides

Final Rejection §102§DOUBLEPATENT
Filed
May 26, 2022
Priority
Jun 28, 2017 — provisional 62/525,803 +3 more
Examiner
ZHANG, KAIJIANG
Art Unit
1684
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
New England Biolabs Inc.
OA Round
2 (Final)
77%
Grant Probability
Favorable
3-4
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
545 granted / 706 resolved
+17.2% vs TC avg
Strong +34% interview lift
Without
With
+34.3%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
26 currently pending
Career history
737
Total Applications
across all art units

Office Action

§102 §DOUBLEPATENT
DETAILED ACTION 1. This action is written in response to applicant’s correspondence filed 6/10/2026. Claims 10-17 and 24-30 were previously withdrawn due to an election/restriction requirement. Claims 18-23 are currently under examination. All the amendments and arguments have been thoroughly reviewed but are found insufficient to place the instantly examined claims in condition for allowance. Specifically, all the rejections are maintained. Double Patenting 2. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 3. Claims 18-23 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 11,371,088. Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-9 of U.S. Patent No. 11,371,088 teach or render obvious all the steps and elements as recited in instant claims 18-23. Specifically, claims 1-3 of U.S. Patent No. 11,371,088 teach all the steps and elements recited in instant claim 18. In addition, the other features as recited in instant claims 19-23 are also taught or rendered obvious by claims 1-9 of U.S. Patent No. 11,371,088. Claim Rejections - 35 USC § 102 4. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. 5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. 6. Claims 18-20 and 22-23 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Uemori et al. (WO 2016/039377 A1, using the published U.S. national stage application, US 2017/0253909 A1, as an English translation). Regarding claim 18 Uemori et al. teach, throughout the whole document, a method for identifying a mismatched nucleotide in a double-stranded nucleic acid, comprising: (a) reacting a sample comprising the double-stranded nucleic acid with EndoMS (i.e., NucS or mismatch-specific endonuclease. See the term “EndoMS” as defined in the paragraph spanning pages 5-6 of the specification as filed) to produce a reaction product, wherein the EndoMS cleaves both strands of the double-stranded nucleic acid only if it contains a mismatch (see paragraphs [0091]-[0092] and [0098], where the “mismatch endonuclease” used is NucS as described in paragraph [0025] and Examples 1-6); (b) subjecting the reaction product of (a) to amplification under conditions that amplify the double-stranded nucleic acid if it is uncleaved but not if it is cleaved (see paragraphs [0091]-[0092] and [0098]); and (c) detecting the presence of an amplification product, wherein the presence of the product indicates that the double-stranded nucleic acid does not have a mismatched nucleotide and the absence of a product indicates that the double-stranded nucleic acid has a mismatched nucleotide (see paragraph [0106]). Regarding claim 19 The method according to Uemori et al., wherein step (b) is done by PCR, using primers that flank the mismatch (see paragraphs [0091]-[0093]). Regarding claim 20 The method according to Uemori et al., wherein mismatch is at a ligation junction (see paragraphs [0091]-[0092] and [0098]. Since the mismatch site is in the internal portion of the double-stranded nucleic acid, such site can be a hypothetical ligation junction (if the double-stranded nucleic acid were to be generated by the ligation of the two corresponding fragments flanking the ligation junction) because any such site can be a hypothetical ligation junction.). Regarding claim 22 The method according to Uemori et al., wherein the double-stranded nucleic acid is genomic DNA (see paragraph [0105]). Regarding claim 23 The method according to Uemori et al., wherein the detecting step (c) comprises quantifying the amount of the amplification product (see paragraph [0111]). Response to Arguments 7. Applicant’s arguments (as filed on 6/10/2026) directed at the rejections have been fully considered but are found to be unpersuasive. Double Patenting Rejection Applicant argues that the Office action has provided no evidence or argument to substantiate its position beyond the conclusory statement that “claims 1-3 of U.S. Patent No. 11,371,088 teach all the steps and elements recited in instant claim 18”. This is not found persuasive because all the steps and elements recited in instant claim 18 are clearly taught by claims 1-3 of U.S. Patent No. 11,371,088. Specifically, claim 1 of U.S. Patent No. 11,371,088 teaches step (a) of the instantly claimed method, where: (1) the sample is the “ligation products that comprise: (i) adapter-ligated double-stranded nucleic acid fragments and (ii) double-stranded adapter dimers that comprise a T:T mismatch at the ligation junction”, and (2) said sample is reacted with EndoMS which cleaves “both strands of the adapter dimers” (because the adapter dimers comprise a T:T mismatch), producing a reaction product comprising only “adapter-ligated double-stranded nucleic acid fragments” (which are uncleaved by EndoMS). Claims 2-3 of U.S. Patent No. 11,371,088 further teach step (b) of the instantly claimed method, where the reaction product, namely the “adapter-ligated double-stranded nucleic acid fragments”, is subjected to amplification under conditions that amplify the double-stranded nucleic acid if it is uncleaved but not if it is cleaved. The amplification as recited in claims 2-3 of U.S. Patent No. 11,371,088 also imply a step of detecting the presence of the amplification product, because the very purpose of the amplification is to obtain the amplification product (which would necessarily involve detecting the presence of the amplification product). Rejection under 35 USC 102 Applicant argued the following: PNG media_image1.png 352 722 media_image1.png Greyscale This is not found persuasive because Uemori et al. do teach forming an EndoMS reaction product and subjecting the EndoMS reaction product to amplification. Specifically, in the method taught by Uemori et al., an EndoMS reaction product is formed in earlier cycles of the amplification process (where any double-stranded nucleic acid having a mismatched base pair generated by incorporation of an incorrect nucleotide during these earlier cycles of the amplification process is cleaved, forming an EndoMS reaction product that has the correct nucleic acid sequence), and said EndoMS reaction product is then subjected to later cycles of the amplification process to produce an amplification product that has “a decreased error rate” (see paragraph [0092]). Conclusion 8. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KAIJIANG ZHANG whose telephone number is (571)272-5207. The examiner can normally be reached Monday - Friday, 8:30 am - 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heather Calamita can be reached at 571-272-2876. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KAIJIANG ZHANG/Primary Examiner, Art Unit 1684
Read full office action

Prosecution Timeline

May 26, 2022
Application Filed
Mar 10, 2026
Non-Final Rejection mailed — §102, §DOUBLEPATENT
Jun 10, 2026
Response Filed
Sep 15, 2026
Final Rejection mailed — §102, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790608
EFFICIENT RANDOM ACCESS TO DNA-ENCODED DATA
4y 5m to grant Granted Nov 10, 2026
Patent 12790642
SCALABLE MULTIPLEX DETECTION OF SOMATIC MUTATIONS
3y 3m to grant Granted Nov 10, 2026
Patent 12781272
PROCESSES AND KITS FOR IDENTIFYING ANEUPLOIDY
5y 0m to grant Granted Nov 03, 2026
Patent 12760361
COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS
5y 3m to grant Granted Oct 13, 2026
Patent 12760353
Reagents And Methods For The Analysis of Linked Nucleic Acids
4y 7m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
77%
Grant Probability
99%
With Interview (+34.3%)
Moderate
PTA Risk
Based on 706 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month